Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02562521 · ClinicalTrials.gov registry record · Phase 4
A Smoking Cessation Intervention for Yale Dining Employees
A Phase 4 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT02562521: Completed Phase 4 study, sponsored by Yale University.
NCT02562521 is a Phase 4 study that has completed, run by Yale University. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02562521, a Phase 4 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a smoking cessation program for employees at the Yale University dining hall. Two pilot dining halls and six paired dining halls (3 test and 3 control sites) will be offered a contingency management/pharmacotherapy smoking cessation intervention at the work site.
Primary Outcome
A survey of dining hall employees will be used to determine the proportion of the dining hall employees who made a quit attempt in the prior six weeks in the treatment and delayed treatment control groups. Values present the proportion of dining hall employees who smoke who reported making a quit attempt.
Interventions
- DRUG Varenicline
- BEHAVIORAL Contingency management
- DRUG Nicotine replacement therapy
- BEHAVIORAL Additional behavioral support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
What the finished NCT02562521 record still lists
NCT02562521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Varenicline is the first listed.
NCT02562521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02562521 about?
NCT02562521 is a clinical study titled "A Smoking Cessation Intervention for Yale Dining Employees". The purpose of this study is to evaluate a smoking cessation program for employees at the Yale University dining hall. Two pilot dining halls and six paired dining halls (3 test and 3 control sites) will be offered a contingency management/pharmacotherapy smoking cessation intervention at the work s...
What is the current status of trial NCT02562521?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2015-09. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02562521?
The interventions under investigation include: Varenicline (DRUG), Contingency management (BEHAVIORAL), Nicotine replacement therapy (DRUG), Additional behavioral support (BEHAVIORAL).
Who is sponsoring clinical trial NCT02562521?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02562521's enrollment target sits among peer trials
25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia